Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct 19;4(4):00084-2018.
doi: 10.1183/23120541.00084-2018. eCollection 2018 Oct.

Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study

Vincent Cottin  1   2 , Dirk Koschel  3 , Andreas Günther  4   5 , Carlo Albera  6 , Arata Azuma  7 , C Magnus Sköld  8   9 , Sara Tomassetti  10 , Philip Hormel  11 , John L Stauffer  11 , Indiana Strombom  11 , Klaus-Uwe Kirchgaessler  12 , Toby M Maher  13   14
Affiliations

Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study

Vincent Cottin et al. ERJ Open Res. .

Abstract

Real-world studies include a broader patient population for a longer duration than randomised controlled trials (RCTs) and can provide relevant insights for clinical practice. PASSPORT was a multicentre, prospective, post-authorisation study of patients who were newly prescribed pirfenidone and followed for 2 years after initiating treatment. Physicians collected data on adverse drug reactions (ADRs), serious ADRs (SADRs) and ADRs of special interest (ADRSI) at baseline and then every 3 months. Post hoc stepwise logistic regression models were used to identify baseline characteristics associated with discontinuing treatment due to an ADR. Patients (n=1009, 99.7% with idiopathic pulmonary fibrosis) had a median pirfenidone exposure of 442.0 days. Overall, 741 (73.4%) patients experienced ADRs, most commonly nausea (20.6%) and fatigue (18.5%). ADRs led to treatment discontinuation in 290 (28.7%) patients after a median of 99.5 days. Overall, 55 (5.5%) patients experienced SADRs, with a fatal outcome in six patients. ADRSI were reported in 693 patients, most commonly gastrointestinal symptoms (38.3%) and photosensitivity reactions/skin rashes (29.0%). Older age and female sex were associated with early treatment discontinuation due to an ADR. Findings were consistent with the known safety profile of pirfenidone, based on RCT data and other post-marketing experience, with no new safety signals observed.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: V. Cottin has received consultancy and lectures fees, and support for travel to medical meetings from Actelion and Roche; has received personal fees for development of educational presentations, consultancy and lectures fees, and support for travel to medical meetings from Boehringer Ingelheim; has received consultancy fees from Bayer and Galapagos; has received personal fees from service on an adjudication committee from Gilead; consultancy fees from GlaxoSmithKline (in 2015) and MSD; has received consultancy and lecture fees from Novartis and Sanofi; is the chair of the data and safety monitoring board (DSMB) of Promedior; and serves on the DSMB of Celgene, all outside the submitted work. Conflict of interest: D. Koschel has received consultancy or speaker fees from AstraZeneca, Boehringer Ingelheim, Grifols, Novartis, Roche/Intermune, Sanofi-Aventis and Teva. Conflict of interest: A. Günther has received research funding from Sanofi, Inventiva and Roche; and consultancy or speaker fees from Boehringer Ingelheim, Roche and Teva. Conflict of interest: C. Albera has received fees from Roche (formerly InterMune), Boehringer Ingelheim, Fibrogen, MSD, GlaxoSmithKline, Bayer and Sanofi for activity as an advisor, consultant or steering committee member; he has also received unrestricted grants from Boehringer Ingelheim. Conflict of interest: A. Azuma has received personal fees from AFT Pharma, Boehringer Ingelheim, InterMune/Roche and Shionogi Co. Conflict of interest: C.M. Sköld has received research funding from Boehringer Ingelheim, Roche and Sandoz; and consultancy or speaker fees from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, InterMune, Meda, Mundipharma, Novartis, Roche, Sandoz and Vicore Pharma. Conflict of interest: S. Tomassetti has received speaker fees from Boehringer Ingelheim and Roche. Conflict of interest: P. Hormel is an employee of Roche-Genentech and holds shares in that company. Conflict of interest: J.L. Stauffer is an employee of Roche-Genentech and holds shares in that company. Conflict of interest: I. Strombom is an employee of Roche-Genentech and holds shares in that company. Conflict of interest: K-U. Kirchgaessler is an employee of Roche-Genentech and holds shares in that company. Conflict of interest: T.M. Maher has received industry academic research funding from GlaxoSmithKline R&D and UCB Pharma; and consultancy or speaker fees from Apellis, AstraZeneca, aTyr Pharma, Bayer, Biogen Idec, Boehringer Ingelheim, Galapagos, GlaxoSmithKline R&D, ProMetic, Roche (and previously InterMune), Sanumed and UCB Pharma.

Figures

FIGURE 1
FIGURE 1
Patient disposition. AE: adverse event; ADR: adverse drug reaction. #: an ADR was defined as any safety event with a possible causal relationship to pirfenidone (the treating physician (investigator) made a clinical judgement to decide if the ADR was related to pirfenidone).
FIGURE 2
FIGURE 2
Dose adjustment and retention in patients who experienced an adverse drug reaction (ADR). #: an ADR was defined as any safety event with a possible causal relationship to pirfenidone (the treating physician (investigator) made a clinical judgement to decide if the ADR was related to pirfenidone).
See this image and copyright information in PMC

References

    1. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183: 431–440. - PubMed
    1. Meltzer EB, Noble PW. Idiopathic pulmonary fibrosis. Orphanet J Rare Dis 2008; 3: 8. - PMC - PubMed
    1. European Medicines Agency. Esbriet (pirfenidone). Summary of Product Characteristics. 2017. www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information... Date last accessed: June 1, 2018.
    1. US Food and Drug Administration. Esbriet. Highlights of Prescribing Information 2017. www.accessdata.fda.gov/drugsatfda_docs/label/2017/208780s000lbl.pdf Date last accessed: June 1, 2018.
    1. Pharmaceuticals and Medical Devices Agency Japan. Pirfenidone Review Report 2008. www.pmda.go.jp/files/000153687.pdf Date last accessed: June 4, 2018.